KalVista Pharmaceuticals (KALV) Net Cash Flow Growth (3y) (2019 - 2025)
KalVista Pharmaceuticals (KALV) Net Cash Flow Growth (3y) (2019 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,861.65 Bn | 66,861.36 Bn | - | -50.33% |
| 2 | Nanobiotix | 1,910.87 Bn | 1,910.81 Bn | - | - |
| 3 | Akari Therapeutics | 989.71 Bn | 989.71 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 38.47% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 33.37% |
| 6 | Regeneron Pharmaceuticals | 69.90 Bn | 61.14 Bn | 3.31 Bn | -29.82% |
| 7 | Belite Bio | 62.74 Bn | 62.74 Bn | - | - |
| 8 | Argenx Se | 55.83 Bn | 50.65 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.46 Bn | 37.46 Bn | - | - |
| 10 | KalVista Pharmaceuticals | 1.36 Bn | 1.36 Bn | 49.41 Mn | -49.52% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 31, 2025 | -49.52% |
| Apr 30, 2025 | -40.03% |
| Oct 31, 2024 | 91.94% |
| Jul 31, 2024 | 70.44% |
| Apr 30, 2024 | -35.47% |
| Jan 31, 2024 | -223.98% |
| Oct 31, 2023 | 98.53% |
| Jul 31, 2023 | -76.60% |
| Apr 30, 2023 | -123.41% |
| Jan 31, 2023 | 151.81% |
| Oct 31, 2022 | 67.08% |
| Jul 31, 2022 | 94.14% |
| Apr 30, 2022 | 16.48% |
| Jan 31, 2022 | 81.85% |
| Oct 31, 2021 | -26.51% |
| Jul 31, 2021 | -7.09% |
| Apr 30, 2021 | 88.03% |
| Jan 31, 2021 | -66.40% |
| Oct 31, 2020 | 40.74% |
| Jul 31, 2020 | 34.49% |